The Venture Codex

Participated · Seed · Dec 2024

Alveron Pharma is a clinical-stage company developing OKL-1111, a synthetic agent intended to reverse anticoagulants and platelet inhibitors and prevent haematoma expansion in intracranial haemorrhage (ICH). OKL-1111 binds to a downstream clotting factor and is designed for rapid IV administration, potentially within 10 minutes of a diagnostic CT scan. The drug also reportedly reverses the effects of clopidogrel, for which there is currently no antidote. Founded in 2019 and based in Nijmegen, Netherlands, Alveron positions OKL-1111 as a first-line therapy to reduce door-to-needle time and improve clinical outcomes including mortality and morbidity. Financially, the company completed a €5.0M Series Seed extension (approx $5.28M) to accelerate development. Proceeds will support activities to ready OKL-1111 for further clinical studies aimed at demonstrating safety and proof-of-concept efficacy in patients.

Participated · Convertible Note · Sep 2021

Xenikos develops immunotherapies based on toxin-conjugated monoclonal antibodies designed to reset the immune system in life‑threatening T cell–mediated conditions. Its flagship product, T‑Guard, targets CD3 and CD7 to selectively eliminate mature T cells and NK cells with a short-lived effect to reduce infection risk. A Phase 1/2 study showed a high complete response rate and a doubling of six‑month overall survival versus institutional historical controls; those results were published in a peer‑reviewed journal. T‑Guard has been granted Orphan Drug Designation in both the EU and the US. The company plans a randomized Phase 3 registrational trial in the US and EU to evaluate T‑Guard versus ruxolitinib for steroid‑refractory acute graft‑versus‑host disease, expected to commence in the second half of 2021. Xenikos is based in Nijmegen, the Netherlands, and recently secured financing to support the Phase 3 program. Xenikos is a Dutch biotech developing a late-stage transplantation medicine. Its core product is a transplantation treatment currently in late-stage development. The company secured $30 million in a Series B financing. Medicxi and RA Capital Management are named participants in the round. Proceeds are intended to push the transplantation medicine through further development. The article does not provide revenue, user metrics, prior fundraising details, or a founding year.